Validation of olfactory deficit as a biomarker of Alzheimer disease
Woodward MR, Amrutkar CV, Shah HC, Benedict RH, Rajakrishnan S, Doody RS, Yan L, Szigeti K.. Neurology. Clinical practice, 2017-02-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Background We evaluated smell identification as a biomarker for Alzheimer disease (AD) by assessing its utility in differentiating normal aging from an amnestic disorder and determining its predictive value for conversion from amnestic mild cognitive impairment (aMCI) to AD. Methods Cross-sectional study (AD = 262, aMCI = 110, controls = 194) measuring smell identification (University of Pennsylvania Smell Identification Test [UPSIT]) and cognitive status was performed, as well as longitudinal analysis of aMCI participants (n = 96) with at least 1 year follow-up (mean 477.6 ± 223.3 days), to determine conversion by National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association criteria. Results Odor identification and disease status were highly correlated after correcting for age, sex, and APOE ( p 7, smeller) had a sensitivity and specificity of 88% and 71% for identifying AD and 74% sensitivity and 71% specificity for identifying an amnestic disorder. A total of 36.4% of participants with impaired olfaction and 17.3% with intact olfaction converted to AD ( p = 0.03). The ROC/AUC for prediction of conversion to AD was 0.62. Conclusions Olfactory identification deficit is a useful screening tool for AD-related amnestic disorder, with sensitivity and specificity comparable to other established biomarkers, with benefits such as ease of administration and low cost. Olfactory identification deficit can be utilized to stratify risk of conversion from aMCI to AD and enrich clinical trials of disease-modifying therapy. Classification of evidence This study provides Class III evidence that smell identification (10-item UPSIT subset) accurately identifies patients with amnestic disorders.
What this study adds
Evidence grade: Moderate
This is a cross-sectional study of 96 participants. A smell identification test distinguished Alzheimer disease and amnestic disorder from normal aging with sensitivity and specificity similar to other established biomarkers. Reported effect size: 36.4%; 17.3%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Woodward, M. R., Amrutkar, C. V., Shah, H. C., Benedict, R. H., Rajakrishnan, S., Doody, R. S., et al. (2017). Validation of olfactory deficit as a biomarker of Alzheimer disease. Neurology. Clinical practice. https://doi.org/10.1212/cpj.0000000000000293
Vancouver
Woodward MR, Amrutkar CV, Shah HC, Benedict RH, Rajakrishnan S, Doody RS, et al. Validation of olfactory deficit as a biomarker of Alzheimer disease. Neurology. Clinical practice. 2017. doi:10.1212/cpj.0000000000000293. PMID: 28243501.
BibTeX
@article{woodward2017-28243501,
author = {Woodward, M. R. and Amrutkar, C. V. and Shah, H. C. and Benedict, R. H. and Rajakrishnan, S. and Doody, R. S. and Yan, L. and Szigeti, K.},
title = {{Validation of olfactory deficit as a biomarker of Alzheimer disease}},
journal = {Neurology. Clinical practice},
year = {2017},
doi = {10.1212/cpj.0000000000000293},
pmid = {28243501},
url = {https://doi.org/10.1212/cpj.0000000000000293}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- Results Odor identification and disease status were highly correlated after correcting for age, sex, and APOE ( p 7, smeller) had a sensitivity and specificity of 88% and 71% for identifying AD and 74% sensitivity and 71% specificity for identifying an amnestic disorder.
Why it matters
A smell identification test distinguished Alzheimer disease and amnestic disorder from normal aging with sensitivity and specificity similar to other established biomarkers. Among people with mild cognitive impairment, those with impaired smell were more likely to develop Alzheimer disease, though the test's predictive accuracy was modest.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Study designcross-sectional
- Participants96
- Effect size36.4%; 17.3%
- Evidence strengthModerate
How this study scored 52/100
Published in a peer-reviewed journal, and it is a snapshot of people at one point in time. Scored zero for randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Neurology. Clinical practice) |
| Journal's citation record | 0 / 4 | Neurology Clinical Practice: journal h-index 60 (OpenAlex, 2026-10-29) |
| Study design | 4 / 12 | A snapshot of people at one point in time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2017 — within 10 year(s) of the newest study here |
| Sample size | 1 / 4 | 96 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 118 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 10.7 citations a year over 11 year(s) since 2017 |
| Impact for its field and year | 3 / 6 | Cited 7.2× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 2 other studies in this library |
| Still being cited | 2 / 4 | Cited 37 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Scott Chasse: h-index 13 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Baylor College of Medicine: institution h-index 1,607 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 28243501) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 52 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1212/cpj.0000000000000293
- PubMed: 28243501
- Original source →
- Free full text: PubMed Central →
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 14.
Later studies that cite this one
2 studies in the alzhub library list this one in their references.
Related studies in Genetics from nearby years
Also tagged “cerebrospinal”
820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.